MacroGenics | MGNX - Gross Profit On Sales


MacroGenics reported $61.25M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Biogen USD 1.65B 34.6M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Daiichi Sankyo JPY 439.83B 95.05B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Genmab DKK 868M 195M Jun/2025
Geron USD 46.71M 525K Dec/2025
Gilead Sciences USD 6.31B 106M Dec/2025
J&J USD 16.6B 118M Dec/2025
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
MacroGenics USD 61.25M 88.71M Sep/2025
Merck USD 13.42B 431M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Roche Holding CHF 22.09B 10.04B Dec/2025
Xencor USD 21M 22.61M Sep/2025